Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 6/20 | 0.40 |
| ▸ | FLT3 | P36888 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524661 | 0.90 | WEE1 (0.45) | JAK2CSF1RCDK6PTK2KIT | |
| SCHEMBL15524637 | 0.88 | JAK3 (0.46) | JAK2CDK6PTK2JAK3ALK | |
| SCHEMBL12478010 | 0.85 | PTK2 (0.53) | PTK2JAK3LCKALKKDR | |
| SCHEMBL15514106 | 0.84 | FLT4 (0.50) | PTK2KITFLT3JAK3LCK | |
| SCHEMBL14576985 | 0.82 | PTK2 (0.49) | PTK2JAK3LCKKDRSYK | |
| SCHEMBL15524486 | 0.80 | PTK2 (0.70) | PTK2 | |
| SCHEMBL10206190 | 0.79 | CCND3 (0.46) | JAK2CDK4CDK6PTK2KIT | |
| SCHEMBL15524488 | 0.79 | PTK2 (0.45) | CSF1RCDK4CDK6PTK2 | |
| SCHEMBL15524247 | 0.78 | PTK2 (0.61) | PTK2 | |
| SCHEMBL15524248 | 0.78 | PTK2 (0.41) | JAK2CSF1RCDK4CDK6PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK2 143/4885CSF1R 118/4885CDK4 46/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK2 86/4885CSF1R 66/4885CDK4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.